

| | | | | |
|---|---|---|--------------------|------------------|
| Patient ID SA00117626 | Patient Name TESTING, ATLAS REPORT ABNORMAL | Birth Date 1994-06-12 | Gender M | Age 24 |
| Order Number SA00117626 | Client Order Number SA00117626 | Ordering Physician CLIENT, CLIENT | Report Notes | |
| Account Information C7028846 DLMP Rochester | | Collected 06 Feb 2019 08:30 | | |

Cryopreserve for Biochem Studies
MCR

Fibroblasts successfully cryopreserved.

Received: 07 Feb 2019 10:55

Reported: 07 Feb 2019 12:25

Fatty Acid Ox Probe Assay, Fibro
Interpretation
1 MCR

POSITIVE

The acylcarnitine profiles revealed the following abnormalities (the concentrations provided correspond to the mean value for triplicate analysis):

 Hexanoylcarnitine (C6):
0.055 nmol/mg protein (99th percentile of reference population: 0.093; N=128)

 Octanoylcarnitine (C8):
0.127 nmol/mg protein (99th percentile of reference population: 0.098; N=128)

 Decanoylcarnitine (C10):
0.067 nmol/mg protein (99th percentile of reference population: 0.147; N=128)

The score of CLIR post-analytical tool for Medium-Chain Acyl-CoA Dehydrogenase (MCAD) deficiency: 266 (informative >150);

percentile rank in comparison to known cases: 87%, N=20)

INTERPRETATION

These results are consistent with MCAD deficiency. We recommend further confirmation by molecular genetic analysis of the MCAD gene. In addition, both parents, and if applicable, all siblings (of any age) should be tested (request urine acylglycines and plasma acylcarnitines). Please contact the Biochemical Genetics consultant or genetic counselor on call (Tel. 1-800-533-1710) if you have any questions.

ADDITIONAL INFORMATION

Fibroblasts Incubated with Enriched Medium Followed by Tandem Mass Spectrometry for Acylcarnitines.

Reviewed By
MCR

Daniel Kraft

Received: 07 Feb 2019 10:55

Reported: 07 Feb 2019 12:08

Fibroblast Culture
MCR

Fibroblasts successfully cultured.

Received: 07 Feb 2019 10:55

Reported: 07 Feb 2019 12:24

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

| Code | Laboratory | Address | Lab Director | CLIA Certificate |
|------|--|--|-----------------------------|------------------|
| MCR | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292 |